000 | 01668na a2200229 4500 | ||
---|---|---|---|
003 | H12O | ||
005 | 20210625062806.0 | ||
008 | 130622s2012 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_91902 _aBautista, José M. _eInstituto de Investigación i+12 |
||
245 | 0 | 0 |
_aPharmGKB summary: very important pharmacogene information for G6PD. _h[artículo] |
260 |
_bPharmacogenetics and Genomics, _c2012 |
||
300 | _a22(3):219-28. | ||
500 | _aFormato Vancouver: McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenet Genomics. 2012 Mar;22(3):219-28. | ||
501 | _aPMID: 22237549 | ||
504 | _aContiene 116 referencias | ||
520 | _aGlucose-6-phosphate dehydrogenase (G6PD) was one of the first genes found to be associated with variable drug response. It is also very polymorphic, with G6PD deficiency found in more than 300 million people worldwide [1]. Here, we provide an overview of G6PD as a very important pharmacogene, and detail genetic variants and haplotypes associated with drug response (Although most G6PD variants are caused by single nucleotide polymorphisms (SNPs) in the coding region of the G6PD gene at the X chromosome, due to the heterogeneity of alleles causing G6PD deficiency; here, we use the term ‘haplotype’ to define the set of linked SNPs in a G6PD variant that are inherited together and that may or may not produce G6PD deficiency). | ||
710 |
_9625 _aInstituto de Investigación imas12 |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7522.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |
||
999 |
_c7522 _d7522 |